Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.

INTRODUCTION Ovarian Cancer is the leading cause of death from gynecological malignancy. The poor prognosis is mainly due to presentation at a late stage and poor response to therapy. Much research is needed to identify diagnostic and prognostic biomarkers as well as therapeutic targets for ovarian cancer. Interleukin-8 is expressed by many tumour types and is known to have mitogenic, motogenic and angiogenic effects on tumour cells. AIMS The aim of this study was to investigate the expression of IL-8 and IL-8 receptors (IL-8RA and IL-8RB) in different histological subtypes of ovarian tumours, as potential prognostic biomarkers in ovarian tumours. MATERIALS AND METHODS Immunohitochemistry was used to study the expression of IL-8 and IL-8 receptors in 115 ovarian tumours including 21 benign tumours, 25 borderline tumours and 69 carcinomas of serous, clear cell, endometrioid and mucinous types. The correlation of expression profile, tumour type, stage, and progression free survival and overall survival was statistically analysed. RESULTS IL-8 and IL-8 receptors were expressed in all types of tumours with variable intensity and subcellular distribution. There was a statistically significant correlation between levels of expression and tumour stage and tumour type, being mostly significant in serous tumours. No correlation with patient progression free survival or overall survival was found. CONCLUSION This is the first study investigating the expression of IL-8 and IL-8 receptors using immunohistochemistry in different types of ovarian tumours, including benign and borderline tumours. IL-8 and IL-8RA are potential prognostic biomarkers and therapeutic targets in ovarian cancer, particularly in ovarian serous carcinoma.

[1]  X. Zhang,et al.  Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. , 2012, Cytokine.

[2]  M. Schindl,et al.  Interleukin‐8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel‐containing chemotherapy , 2001, Cancer.

[3]  S. Ferrero,et al.  The preoperative diagnosis of borderline ovarian tumors: a review of current literature , 2012, Archives of Gynecology and Obstetrics.

[4]  F. Muggia Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. , 2009, Gynecologic oncology.

[5]  C. Gilks,et al.  Ovarian carcinoma pathology and genetics: recent advances. , 2009, Human pathology.

[6]  Rakesh K. Singh,et al.  CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. , 2011, Microvascular research.

[7]  B. Davidson,et al.  Borderline ovarian tumours. , 2012, Best practice & research. Clinical obstetrics & gynaecology.

[8]  C. Figdor,et al.  Cytokine Profiles in Cyst Fluids From Ovarian Tumors Reflect Immunosuppressive State of the Tumor , 2011, International Journal of Gynecologic Cancer.

[9]  S. Araki,et al.  Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. , 2007, Cancer research.

[10]  I. Fidler,et al.  Interleukin 8: an autocrine growth factor for human ovarian cancer. , 2001, Oncology research.

[11]  B Rachet,et al.  Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data , 2011, Lancet.

[12]  K. Rabe,et al.  Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. , 2007, Lung cancer.

[13]  S. Kassim,et al.  Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. , 2004, Clinical biochemistry.

[14]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[15]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[16]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[17]  D. Trisciuoglio,et al.  Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. , 2009, European journal of cancer.

[18]  Liz Y. Han,et al.  Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. , 2008, Journal of the National Cancer Institute.

[19]  W. Mcguire Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Ting,et al.  Taxol-dependent Transcriptional Activation of IL-8 Expression in a Subset of Human Ovarian Cancer , 1996 .

[21]  M. Brännström,et al.  Upregulation of interleukin‐8 and polarized epithelial expression of interleukin‐8 receptor A in ovarian carcinomas , 2000, Acta obstetricia et gynecologica Scandinavica.

[22]  K. Xie,et al.  Interleukin-8 and human cancer biology. , 2001, Cytokine & growth factor reviews.

[23]  G. Mills,et al.  CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis , 2010, Clinical Cancer Research.

[24]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[25]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[26]  D. Landsittel,et al.  Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. , 2006, Gynecologic oncology.